
    
      Participants with relapsed/refractory CD19-positive Diffuse Large B-cell Lymphoma and
      Follicular Lymphoma can participate if all eligibility criteria are met.Tests required to
      determine eligibility include disease assessments, a physical exam, Electrocardiograph,
      CT/MRI , and blood draws.Participants receive chemotherapy prior to the infusion of CD19 CAR+
      T cells. After the infusion, participants will be followed for side effects and effect of
      CD19 CAR+ T cells. Study procedures may be performed while hospitalized.
    
  